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The skin not only acts as a physical
barrier to pathogens and toxins, but
also functions as an immunological
barrier constantly responding to envi-
ronmental insults (e.g., UV radiation,
chemical carcinogens, and oncogenic
viruses). Resident and recruited
immune cells respond to these types
of insults by directly or indirectly
inducing secretion of damage response
molecules (e.g., proinflammatory cyto-
kines, chemokines, matrix remodeling
enzymes, reactive oxygen mediators,
and so on) in an attempt to clear
damaged cells and pathogens such that
tissue homeostasis can be reinstated.
Instead, when damage is chronic and/
or results in somatic alterations leading
to altered proliferative or apoptotic
programming of epithelial cells, inflam-
mation that was initially an acute
response instead becomes chronic. In
this scenario, chronic inflammation
acts as a promoting force that fosters
early neoplastic progression and under-
scores data revealing that chronic
exposure to environmental toxins and
pathogens is a risk factor for cancer
development (Coussens and Werb,
2002).
How does activation of what should
be an acute response instead foster
neoplasia? The series of events discussed
above is initiated by tissue-resident
innate immune cells (dendritic cells,
mast cells, macrophages, and gd T cells)
responding to damage response pro-
teins, including damage-associated
molecular patterns, pathogen-associated
molecular patterns, Toll-like receptor
ligands, colony stimulating factors, cyto-
kines (tumor necrosis factor-a), and
chemokines released from ‘‘damaged’’
epithelial cells (Balkwill et al., 2005;
Balkwill, 2009). Upon engagement of
these damage signals, resident immune
cells are activated, and they respond by
degranulation or secretion of a diver-
sity of mediators that in turn results in
activation of resident mesenchymal
support cells (fibroblasts, adipocytes,
mural, and endothelial cells), recruit-
ment of peripheral blood leukocytes into
‘‘damaged’’ tissue, as well as
engagement of cells of the adaptive
immune system, both locally and
peripherally (Balkwill et al., 2005).
Dendritic cells, and to a lesser extent
macrophages, are antigen-presenting
cells that activate B and T cells to
mount an adaptive immune response.
Upon antigen recognition, B cells, as
well as CD4þ and CD8þ T cells,
undergo clonal expansion and mount
responses specific to presented anti-
gens. Although all of these tissue res-
ponses are otherwise entirely ‘‘normal,’’
during early neoplasia, they fail to
resolve (Dvorak, 1986). Thus, chronic
inflammation underlies the earliest
stages of cancer development (Balkwill
and Mantovani, 2001; Coussens and
Werb, 2001, 2002). As such, chronic
inflammation is now accepted as a
hallmark of cancer development
(Hanahan and Weinberg, 2011), where
both innate and adaptive immune cells
exert either pro- or anti-tumor activities
dependent on their activation state and
the microenvironment in which they
reside (Balkwill et al., 2005; de Visser
et al., 2006; Hanahan and Coussens,
2012). Although early studies of skin
focused on the suppressive effects of
leukocytes on carcinogenesis, we now
recognize that proliferation and survival
of epithelial cells harboring genomic
alterations are sustained by chronic
inflammatory pathways; understanding
the nuances of these support mecha-
nisms has yielded a diversity of new
anticancer targets currently being
utilized in the clinic.
ANTITUMOR PROPERTIES OF IMMUNE
CELLS
The antitumor activities of immune
cells were first harnessed in the late
nineteenth century when Coley injec-
ted bacterial mixtures as therapy for
sarcomas after noting that cancer
patients who had subsequently
acquired acute infections developed
spontaneous tumor regression (Coley,
1891). Although the basis for tumor
regression was not understood at the
time, it was the first evidence that the
immune system could be harnessed for
cancer therapy; we now know that
cytotoxic T cells were responsible for
Coley’s observed tumor regressions
(Bickels et al., 2002). More recent
studies reporting antitumor roles for
the immune system are clinical studies
reporting that organ transplant reci-
pients receiving long-term immuno-
suppressants exhibit increased relative
risk for squamous cell carcinomas
(Hardie et al., 1980; Hartevelt et al.,
1990). It has subsequently been revea-
led that increased relative risk is in part
because of major histocompatibility
complex class I and II genes respon-
sible for antigen presentation to cyto-
toxic T cells (Bouwes Bavinck et al.,
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1991a, b), as well as infections by
human papilloma viruses and UV
exposure in a setting where T cells
are incapable of responding (de Visser
et al., 2006).
Studies led by Schreiber and collea-
gues were among the first to charac-
terize tumor-specific antigens. These
studies revealed that CD8þ T cells
become licensed by specific tumor
antigens, thus representing structures
against which antitumor immune
responses are elicited (Schreiber et al.,
1988; Ward et al., 1989). Antigens in
this form represent protein products of
mutant genes, overexpressed genes, or
viral genes (Cheever et al., 2009).
However, the immune system is also
continually sculpting tumors (i.e.,
immunoediting), as was evidenced by
work from Schreiber et al. (2011).
Immunoediting occurs in three stages:
elimination, equilibrium, and escape.
The elimination phase consists of the
innate and adaptive arms of the
immune system working in concert to
destroy cancer cells. In the event that
mutated cells are not eliminated, the
equilibrium phase ensues wherein
leukocytes interact with neoplastic
cells and maintain a state of dor-
mancy. The escape phase is entered
once neoplastic cells become less
immunogenic, evade host immune
responses, or actively immunosup-
press the host, resulting in tumor
outgrowth and progression (Schreiber
et al., 2011).
The functional significance of cyto-
toxic T lymphocytes in skin carcino-
genesis was first revealed in a
UV-induced experimental tumor
model in which depletion of CD8þ T
cells correlated with enhanced tumor
growth in immunocompetent mice
(Fortner and Kripke, 1977). Cytotoxic
CD8þ T cells respond to tumor-speci-
fic antigens and mediate antitumor
responses via expression of IFN-g and
granzymes. Progressing tumors (escape
phase) often overcome cytotoxic T-cell
specificity by reducing expression of
IFN-g receptors, loss of antigen expres-
sion, and reduced major histocompa-
tibility complex expression. Although
IL-10 has historically been thought
to contribute to immunosuppressive
environments and reduced antitumor
activity, it was recently reported that
IL-10 in skin induces CD8þ T-cell
tumor infiltration, directly leading to
increased expression of IFN-g, gran-
zymes, and intratumoral major histo-
compatibility complex molecules,
thereby restoring tumor immuno-
surveillance in late-stage tumors
(Mumm et al., 2011; Emmerich et al.,
2012). Another mechanism by which
CD8þ T cells and natural killer T cells
can escape immunosurveillance was
revealed using mice overexpressing the
stress antigen major histocompatibility
complex class Ib molecule Rae-1.
CD8þ T cells and natural killer
T cells express the Rae-1 receptor
NKG2D, and thus recognize and lyse
damaged cells expressing Rae-1
(Oppenheim et al., 2005). Overexpres-
sion of Rae-1, representing chronically
stressed cells, results in downregulation
of NKG2D on CD8þ T cells and
natural killer T cells, thus rendering
them anergic and enabling immune
evasion, thereby increasing cancer
incidence and progression (Girardi
et al., 2004; Oppenheim et al., 2005).
Together, these studies indicate that
immunosurveillance and response to
tumor antigens is a critical aspect of
cancer suppression/regression.
Langerhans cells (LCs) residing in
epidermal layers of squamous epithe-
lium are thought to represent initial
antigen-presenting cells encountering
tumor antigens (Lewis et al., 2010). LCs
sample their surrounding microenvi-
ronment for antigens, and upon
encountering such, traffic via dermal
lymphatic vessels to skin-draining
lymph nodes where they present anti-
gen to T cells (Lewis et al., 2010). Their
protective role against carcinogenesis
was initially demonstrated by Grabbe
et al. (1991) using in vivo models.
Epidermal cells from control mice and
Thy-1-depleted epidermal cells were
preincubated with tumor fragments.
Cell suspensions were then injected
into syngeneic mice and when challen-
ged with tumor cells, neither
the untreated epidermal cells nor the
Thy-1-depleted epidermal cells were
protected against tumor challenge,
indicating that LCs participated in
antitumor immunity (Grabbe et al.,
1991). However, it should be noted
that this role may be dependent on the
tumor context, as it has recently been
reported that LCs are also responsible
for metabolism of 7,12-dimethylbenz
[a]anthracene (DMBA) into its muta-
genic metabolite DMBA-trans-3,4-diol;
mice lacking LCs are resistant to
DMBA-induced carcinogenesis and
exhibit reduced DNA damage, inclu-
ding fewer HRas mutations (Strid et al.,
2008; Modi et al., 2012).
The gd T cells (dendritic epidermal T
cells) are resident epithelial T cells
expressing restricted or invariant TCR-
g and -d genes. In murine epidermis,
dendritic epidermal T cells function in
immunosurveillance; they respond to
stress and other self-antigens expressed
by damaged or diseased keratinocytes,
and they directly lyse damaged cells
(Kaminski et al., 1993; Girardi, 2006).
The role of dendritic epidermal
T cells in tumor immunosurveillance
was highlighted by Girardi et al.
(2001), where they revealed increased
susceptibility to cutaneous malig-
nancies induced by DMBA/12-O-tetra-
decanoylphorbol-13-acetate (TPA) in
gd T cell–deficient mice. One mechan-
ism by which dendritic epidermal T
cells may regulate tumor development
in this context is via NKG2D recogni-
tion of the stress ligand Rae1 that is
induced upon DMBA/TPA treatment
(Girardi et al., 2001). As is the case
with the CD8þ T cells described
above, gd T cells expressing NKG2D
can kill Rae-1-expressing cells in vitro,
thus demonstrating their cytolytic acti-
vity toward damaged and stressed cells
(Girardi et al., 2001; Oppenheim et al.,
2005).
PROTUMOR PROPERTIES OF IMMUNE
CELLS
Although the antitumor properties of the
immune system are well appreciated,
there is now also ample evidence that
select subtypes of leukocytes also pro-
mote tumorigenesis. Virchow first
reported the presence of leukocytes in
tumors in the nineteenth century and
hypothesized that tumors arise at sites
of chronic inflammation (Balkwill
and Mantovani, 2001). Although later
studies have confirmed the link between
chronic inflammation and increased
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incidence of tumor development
(Balkwill and Mantovani, 2001), the
functional role of immune cells in
tumorigenesis has only recently begun
to be elucidated.
Among the first immune cells reco-
gnized as having a protumoral role in
neoplastic progression were mast cells,
based on in vivo studies in the K14-
HPV16 mouse model of squamous
carcinogenesis (Coussens et al., 1999).
Mast cells were found to release matrix
remodeling proteolytic enzymes, inclu-
ding mast cell protease-4 and -6
and matrix metalloprotease-9, that in
turn activate fibroblasts and initiate
angiogenesis (Coussens et al., 1999,
2000). Subsequent studies elucidated
mechanisms by which myeloid cells,
including mast cells and macrophages,
are recruited to premalignant tissue
and foster ongoing tumor develop-
ment. B cells, which are activated in
the periphery by antigen-presenting
cells, secrete autoantibodies that form
circulating immune complexes that
accumulate in neoplastic stroma as
the vasculature becomes leaky and
angiogenic (de Visser et al., 2005).
The circulating immune complexes
interact with activating Fcg receptors
(FcgRI and III), leading to activation of
FcgR-dependent signaling cascades in
myeloid cells that in turn foster pro-
tumoral programs critical for cancer
development (Andreu et al., 2010). The
significance of this process is illustrated
by studies where absence of B cells
in premalignant tissue or in squamous
cell carcinomas of tumor-prone mice,
by either genetic ablation or B-cell
depletion via administration of B cell–
depleting aCD20 antibody, prevents or
limits circulating immune complex
deposition, impedes recruitment and
activation of protumoral-type leuko-
cytes, and thereby limits neoplastic
progression (Andreu et al., 2010;
Affara et al., 2014).
Tumor necrosis factor-a is an impor-
tant proinflammatory cytokine secreted
by epithelial cells, mast cells, macro-
phages, and T cells involved in neo-
plastic progression of several cancer
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Figure 1. Putative targets for combinational immunotherapy in squamous carcinogenesis. Pro- and antitumor activities of resident and recruited immune cells
during squamous carcinogenesis are depicted. Neoplastic epidermis is shown progressively acquiring invasive/malignant properties (left to right) and invading
into ectopic dermis. Resident and recruited immune cells, and their effector molecules, are depicted in black, with targets for therapeutic intervention shown in
red. By combining immunological targets with chemotherapy and/or radiotherapy in patients harboring favorable immunoscores, durable antitumor responses
are likely to be achieved as compared with conventional cytotoxic monotherapy. Arg1, arginase-1; BTKi Bruton’s tyrosine kinase inhibitor; CAR, chimeric
antigen receptor T cells; Col, collagen; CTLA-4, cytotoxic T-lymphocyte antigen-4; CTX, chemotherapy; dDC, dermal dendritic cell; DETC, dendritic epidermal
T cell; dLN, draining lymph node; EGF, epidermal growth factor; FcgR, immunoglobulin Fc g receptor; FGF, fibroblast growth factors; GZM, granzyme; HDAC,
histone deacetylase; HPV, human papilloma virus; IC, immune complex; Lam, laminin; LC, Langerhans cell; MF, macrophage; MCP, mast cell protease; MHCII,
major histocompatibility class II; MMP, matrix metalloproteinase; MPO, myeloperoxidase; NKT cell, natural killer T cell; OSM, oncostatin M; PD-L1,
programmed death ligand-1; PMN, polymorphonuclear leukocyte; RTX, radiotherapy; Syki, Syk kinase inhibitor; VEGF, vascular endothelial growth factor.
MILESTONES | CUTANEOUS BIOLOGY SEPTEMBER 2014 E25
types, including chemically induced
squamous cancers. Mice lacking tumor
necrosis factor-a are largely resistant to
tumor formation following adminis-
tration of DMBA/TPA (Moore et al.,
1999), where IL-10-secreting B regula-
tory cells and CD4þ T cells play
important roles in regulating terminal
phenotypes (Schioppa et al., 2011).
Other mechanisms by which
immune cells can be recruited to sites
of chronic inflammation are by expres-
sion of CXC chemokine receptors
(CXCRs). CXCR2 is primarily expressed
on neutrophils and is a key regulator of
their recruitment and effector responses
(Cacalano et al., 1994). Cutaneous
activation of protein kinase C, either
by TPA or in oncogene-expressing
transgenic mice, results in secretion of
cytokine-induced neutrophil chemo-
attractant and macrophage inflamma-
tory protein 2, leading to recruitment
of CXCR2þ neutrophils (Cataisson
et al., 2006). It has been reported that
CXCR2-deficient mice exhibit reduced
chemotaxis of neutrophils and a corres-
ponding reduction in tumorigenesis in
DMBA/TPA-treated mice, indicating
that targeting protumorigenic neutro-
phils may be therapeutically effica-
cious (Jamieson et al., 2012).
CONCLUDING REMARKS
Malignant tumors generally evolve by
developing mechanisms to evade anti-
tumor immune-based programs
embedded in the tissues in which they
reside, or by instead conscripting them
to promote various hallmarks of carci-
nogenesis (Hanahan and Coussens,
2012). Based on these observations,
targeted immunotherapies should strive
to either enhance the antitumor pro-
perties of immune cells, mitigate the
protumor properties of immune cells,
or a combination of the two. Perhaps
one of the most significant immuno-
modulating therapies recently deve-
loped with demonstrated efficacy in
melanoma is an antibody to cytotoxic
T lymphocyte antigen 4 (CTLA4,
ipilimumab) that inhibits the nega-
tive regulatory activity of CTLA4 on
cytotoxic T cells and T regulatory
cells (Chambers et al., 2001; Wing
et al., 2008). Clinical results from a
randomized phase III trial for relapsed-
refractory metastatic melanoma with
ipilimumab indicated a 2-fold survival
benefit at 12–15 months, thus leading
to its recent Food and Drug Adminis-
tration (FDA) approval (Hodi et al.,
2010). Although successes such as
those observed with ipilimumab embol-
den immunotherapy approaches, the fact
that the majority of patients receiving the
drug failed to respond indicates that other
protumoral mechanisms will also require
targeting in order to achieve durable
remissions for all patients. Combining
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Figure 2. Timeline of milestones in skin tumor immunology that have demonstrated the pro- and antitumor properties of immune cells and their mediators.
Also depicted are immunomodulating therapies that have been used in the past or have current Food and Drug Administration (FDA) approval. CTLA-4,
cytotoxic T-lymphocyte antigen-4; CXCR2, CXC chemokine receptor-2; FcgR, immunoglobulin Fc g receptor; HLA, human leukocyte antigen; MMP-9, matrix
metalloproteinase-9; SCC, squamous cell carcinoma; TNF-a, tumor necrosis factor-a.
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immune-based therapies with conven-
tional chemotherapy, radiotherapy, or
targeted therapy based on tumor immuno-
metrics, e.g., immunoscore (Galon et al.,
2013), are likely to be the next gene-
ration of personalized cancer therapies
(Coussens et al., 2013), and aid in new
approaches going forward (Figure 1).
The skin serves as a vital barrier
between the host and a harsh environ-
ment. Resident and recruited leuko-
cytes are constantly serving critical
roles in maintaining tissue homeostasis,
but in instances of chronic inflamma-
tion, they paradoxically contribute to
every stage of cancer progression.
The models outlined above, including
UV-induced tumorigenesis, chemical
carcinogenesis, and the K14-HPV16
mouse model of squamous carcino-
genesis, have been indispensable for
understanding the role of the immune
system in cancer initiation and progres-
sion (Figure 2), and we expect many
additional milestones in tumor immu-
nology to be revealed using the skin as
a model system.
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